Objective To analyze the clinical correlation of PTTG and VEGF- C expression and epidermal growth factor receptor (EGFR) gene mutation with the pathological features and clinical prognosis for NSCLC (non- small cell lung cancer) patients. Methods From January 2015 to January 2016, 100 cases of non- small cell lung cancer patients were selected as the research objects. The expression of PTTG and VEGF- C in patients with protein and mRNA were detected by immunohistochemistry and real- time fluorescence quantitative PCR. The prognosis and the clinical and pathological features were analyzed. Results The differences between PTTG and VEGF- C expression with age, gender, smoking, pathological types were not significant (P ＞0.05). The differences between expression and prognosis in treatment of PTTG and VEGF-C were significant (P ＜ 0.05). PTTG positive rate was 77.4％ in cases with survival time ≤3 years, 42. 1 ％ in cases more than 3 years. VEGF- C positive rate was 77.4％ in cases with survival time ≤ 3 years, 44.7％ in cases more than 3 years (P ＜0.05). The difference between EGFR gene mutation and the patient's age, smoking were not significant (P ＞0.05). EGFR mutation detection rate of female patients with non- small cell carcinoma was 18％, which was higher than the male 6％. EGFR mutation detection rate of adenocarcinoma was 19.1％ higher than that of squamous cell carcinoma 6.7％ and large cell carcinoma 0％. EGFR gene mutation detection rate in cases of less than 3 years was 1.6％ lower than that more than 3 years 28.9％ (P ＜0.05). Conclusion The expressions of PTTG and VEGF- C can promote the formation of lymphatic microvessel and the lymph node metastasis of tumor cells. The EGFR gene mutation is commonly seen for the patients with adenocarcinoma; the PTTG and VEGF- C expressions and the EGFR gene mutation can be considered as the indicators of the patient's clinical prognosis.%目的 探讨垂体肿瘤转化基因(PTTG)、血管内皮细胞生长因子-C(VEGF-C)的表达以及表皮生长因子受体(EGFR)基因突变与非小细胞肺癌临床病理特征和预后之间的关系.方法 回顾性选取2015年1月至2016年1月接收治疗的非小细胞肺癌患者100例作为研究对象,通过免疫组化和实时荧光定量PCR对患者PTTG及VEGF-C蛋白和mRNA的表达进行检测,结合预后和临床病理特征进行分析.结果 PTTG和VEGF-C的表达与患者的年龄、性别、吸烟情况、病理类型之间无相关性(P＞0.05);PTTG和VEGF-C的表达在不同预后之间具有相关性(P＜0.05);存活时间≤3年PTTG阳性率为77.4％,存活时间＞3年阳性率为42.1％;存活时间≤3年VEGF-C阳性率为77.4％,存活时间＞3年阳性率为44.7％.存活时间≤3年PTTG、VEGF-C阳性率明显高于存活时间＞3年(P＜0.05);EGFR基因突变和患者的年龄、吸烟情况之间无相关性(P＞0.05);非小细胞癌女性患者的EGFR基因突变检出率为18.0％,高于男性的6.0％,腺癌EGFR基因突变检出率19.1％高于鳞癌的6.7％,同时高于大细胞癌的0.0％,存活时间≤3年的EGFR基因突变检出率1.6％低于存活时间＞3年的28.9％(P＜0.05).结论 PTTG、VEGF-C的表达能够促形成肿瘤微淋巴管,从而促使肿瘤细胞淋巴结发生转移;EGFR基因突变更多见于腺癌,PTTG、VEGF-C的表达和EGFR基因突变可以用作判断患者预后的指标.
展开▼
